North American Cannabis Holding to Feature Sports Nutrition Line For $3 B CBD Market at Arnold Schwarzenegger Sports Festival

DALLAS, Jan. 23, 2018 -- Via OTC PR Wire -- North American Cannabis Holdings, Inc. (OTCPINK:USMJ) today announced the Company will join Puration, Inc. (OTCPINK:PURA) to feature the EVERx CBD Infused Sports Nutrition Products at Arnold Schwarzenegger’s Annual Arnold Sports Festival (formerly the Arnold Classic) in Columbus, Ohio March 1-4, 2018. North American Cannabis Holdings will also introduce at the Arnold Sports Festival, the Company’s latest fitness focused restaurant openings and new openings coming soon. The EVERx Sports Nutrition line has been developed by Puration and market tested in North American Cannabis Holdings fitness focused restaurants. EVERx CBD Infused Sports Water was introduced last year at the Arnold and has since become a leading brand name in the CBD infused marketplace and one of the only CBD infused products in the sports nutrition marketplace. Puration will officially launch its new Strawberry Kiwi and Lemon Lime flavored EVERx CBD Infused Sports Waters at the festival. Puration plans to announce additional EVERx CBD Infused Sports Nutrition and Wellness products to be introduced at the Arnold over the next few weeks leading up to the event. All EVERx products are developed with vital input from North American Cannabis Holdings fitness focused restaurants. Puration also plans to announce in the coming weeks sponsorship and spokesperson engagements in conjunction with the Arnold Sports Festival. This year is the 30^th Anniversary of the Arnold Sports Festival which is now host to more athletes than the Olympics with over 70 sporting events and 18,000 athletes. The Arnold will include an Expo with over 1,000 booths.

For more information on EVERx visit www.drinkeverx.com

For more information on North American Cannabis Holdings and Puration visit
www.aciconglomerated.com

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

For More Information Contact:
Steven Rash,
[email protected]
1-800-861-1350